Daniel Isquith
Overview
Explore the profile of Daniel Isquith including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
89
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang D, Naumova A, Isquith D, Sapp J, Huynh K, Tucker I, et al.
Cardiovasc Diabetol
. 2024 Jun;
23(1):197.
PMID: 38849829
Objective: Sodium glucose cotransporter 2 (SGLT2) inhibitors significantly improve cardiovascular outcomes in diabetic patients; however, the mechanism is unclear. We hypothesized that dapagliflozin improves cardiac outcomes via beneficial effects on...
2.
Wang D, Naumova A, Isquith D, Sapp J, Huynh K, Tucker I, et al.
Res Sq
. 2024 Apr;
PMID: 38585865
Objective: Sodium glucose cotransporter 2 (SGLT2) inhibitors significantly improve cardiovascular outcomes in diabetic patients; however, the mechanism is unclear. We hypothesized that dapagliflozin improves cardiac outcomes via beneficial effects on...
3.
Han T, Paramsothy P, Hong J, Isquith D, Xu D, Bai H, et al.
Int J Cardiovasc Imaging
. 2020 Feb;
36(3):481-489.
PMID: 32020410
Previous studies demonstrated that men were more likely to have plaque rupture and are at greater risk for myocardial infarction and stroke than women. We evaluated differences in carotid plaque...
4.
Zhao X, P Phan B, Davis J, Isquith D, Dowdy A, Boltz S, et al.
J Clin Lipidol
. 2016 Sep;
10(5):1091-7.
PMID: 27678425
Background: Cardiovascular disease (CVD) begins early in life and is associated with both the number of risk factors present and length of exposure to these risk factors including hyperlipidemia. Objectives:...
5.
Ronsein G, Hutchins P, Isquith D, Vaisar T, Zhao X, Heinecke J
Arterioscler Thromb Vasc Biol
. 2015 Dec;
36(2):404-11.
PMID: 26681752
Objective: We investigated relationships between statin and niacin/statin combination therapy and the concentration of high-density lipoprotein particles (HDL-P) and cholesterol efflux capacity, 2 HDL metrics that might better assess cardiovascular...
6.
Borja M, Ng K, Irwin A, Hong J, Wu X, Isquith D, et al.
J Lipid Res
. 2015 Aug;
56(10):2002-9.
PMID: 26254308
HDL is the primary mediator of cholesterol mobilization from the periphery to the liver via reverse cholesterol transport (RCT). A critical first step in this process is the uptake of...
7.
Chen H, Sun J, Kerwin W, Balu N, Neradilek M, Hippe D, et al.
J Cardiovasc Magn Reson
. 2014 Aug;
16:51.
PMID: 25084698
Background: The aim of this study is to investigate the inter-scan reproducibility of kinetic parameters in atherosclerotic plaque using dynamic contrast-enhanced (DCE) cardiovascular magnetic resonance (CMR) in a multi-center setting...
8.
P Phan B, Munoz L, Shadzi P, Isquith D, Triller M, Brown B, et al.
Am J Cardiol
. 2012 Nov;
111(3):352-5.
PMID: 23168285
Although the effect of niacin on the glucose levels in subjects with diabetes mellitus has been investigated, niacin's effects on the glucose levels and atherosclerosis in subjects with normal glucose...
9.
Barmar B, Dang Q, Isquith D, Buysse D, Unruh M
Am J Kidney Dis
. 2009 Jan;
53(4):665-72.
PMID: 19131149
Background: Patients with kidney failure have more sleep symptoms than the general population, but the contribution to sleep symptoms of kidney failure versus its treatment with thrice-weekly hemodialysis has been...